Shanta V, Krishnamurthi S
Clin Radiol. 1977 Jul;28(4):427-9. doi: 10.1016/s0009-9260(77)80157-8.
A concurrent randomised controlled clinical trial to evaluate a combination of Bleomycin and radiation as against radiation only in the treatment of advanced oral cancer has been conducted at the Cancer Institute, Madras, since 1971. All T3 and T4 previously untreated oral squamous cell carcinomas with N0, N1 and N2 regional nodes, or N3 nodes confined to the submandibular region, without systemic metastases or gross infiltration of the temporal and infratemporal fossa producing total trismus, and in decent general health were eligible for the trial. Patients with gross active pulmonary tuberculosis were excluded, as were recurrent carcinomas. Age, external fungation of growth or radiological bone invasion were no bar. Randomisation was done by the sealed envelope technique. The study group received concurrent fractionated cobalt 60 teletherapy using two opposing fields and 10-15 mg of Intra-arterial or Intravenous Bleomycin. The controls received fractionated cobalt teletherapy and i.v. or i.m. distilled water on the same protocol as the Bleomycin cases. All cases were evaluated double blind 8 weeks after the end of radiation therapy, and were classified as 'favourable response' or 'failure'. The criterion of 'favourable response' was 'total clinical healing of the tumour within the volume of irradiation with no subsequent recurrence within that volume, whatever the length of follow up'. Anything else was reported as a failure. A long term follow up of 3 years is also available. 136 cases have completed the trial. The favourable response in the study group was 77% as against 20.9% in the control group. The differential response is statistically significant. The present study is the fourth in the series of combined therapeutic trials conducted in advanced oral squamous cell carcinoma since 1958. (Krishnamurthi and Shanta, 1963, 1965, 1967 and 1971). A concurrent randomised controlled clinical trial to evaluate the combination of Bleomycin and radiation as against radiation only in treatment of advanced oral cancer has been conducted at the Cancer Institute, Madras since 1971.
自1971年起,马德拉斯癌症研究所在开展了一项同期随机对照临床试验,以评估博来霉素与放疗联合使用相较于单纯放疗在晚期口腔癌治疗中的效果。所有T3和T4期、先前未经治疗的口腔鳞状细胞癌患者,区域淋巴结为N0、N1和N2,或局限于下颌下区域的N3淋巴结,无全身转移或颞下窝严重浸润导致完全牙关紧闭,且总体健康状况尚可的患者均符合试验条件。有明显活动性肺结核的患者以及复发性癌患者被排除在外。年龄、肿瘤外生性生长或放射学骨侵犯均不是排除标准。随机分组采用密封信封技术。研究组接受同期分割钴60远距离治疗,使用两个相对野,并给予10 - 15毫克动脉内或静脉内博来霉素。对照组接受分割钴远距离治疗,并按照与博来霉素组相同的方案给予静脉内或肌内注射蒸馏水。所有病例在放疗结束8周后进行双盲评估,并分为“良好反应”或“失败”。“良好反应”的标准是“照射范围内肿瘤完全临床治愈,且该范围内无后续复发,无论随访时间多长”。其他情况均报告为失败。也有3年的长期随访结果。136例患者完成了试验。研究组的良好反应率为77%,而对照组为20.9%。差异具有统计学意义。本研究是自1958年以来在晚期口腔鳞状细胞癌中进行的联合治疗试验系列中的第四个。(克里希纳穆尔蒂和尚塔,1963年、1965年、1967年和1971年)。自1971年起,马德拉斯癌症研究所在开展了一项同期随机对照临床试验,以评估博来霉素与放疗联合使用相较于单纯放疗在晚期口腔癌治疗中的效果。